Director, Cardiovascular Research Advanced Education, MedStar Heart and Vascular Institute, Washington, DC, USA.
Cleve Clin J Med. 2017 Dec;84(12 Suppl 4):e20-e24. doi: 10.3949/ccjm.84.s4.05.
Drug-eluting stents (DES) are increasingly being used as a less invasive alternative to coronary artery bypass grafting. Early generation DES had durable polymers that provided acceptable efficacy outcomes but had high rates of stent thrombosis leading to myocardial infarction and death. Second-generation DES have improved outcomes by reducing stent thrombosis and recurrent stenosis. Newer DES with biodegradable polymers have similar efficacy as second-generation DES, but have higher rates of stent thrombosis. This review compares outcomes of bioresorbable scaffolds and looks at stent technology developments that may improve outcomes.
药物洗脱支架(DES)作为一种侵入性较小的冠状动脉旁路移植术替代方法,越来越多地被应用。早期的 DES 具有耐用的聚合物,可提供可接受的疗效,但支架血栓形成的发生率较高,导致心肌梗死和死亡。第二代 DES 通过降低支架血栓形成和再狭窄的发生率,改善了治疗效果。具有生物可降解聚合物的新型 DES 与第二代 DES 具有相似的疗效,但支架血栓形成的发生率更高。本综述比较了生物可吸收支架的结果,并探讨了可能改善治疗效果的支架技术进展。